D. E. Shaw & Co., Inc. Passage Bio, Inc. Transaction History

D. E. Shaw & Co., Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.66 - $1.01 $82,014 - $125,506	-124,264 Reduced 92.53%	10,026 $6,000
Q2 2023 Aug 14, 2023	SELL	$0.82 - $1.19 $114,836 - $166,653	-140,045 Reduced 51.05%	134,290 $126,000
Q1 2023 May 15, 2023	SELL	$0.96 - $1.88 $84,880 - $166,223	-88,417 Reduced 24.37%	274,335 $263,000
Q4 2022 Feb 14, 2023	SELL	$1.06 - $1.48 $17,367 - $24,248	-16,384 Reduced 4.32%	362,752 $500,000
Q3 2022 Nov 14, 2022	BUY	$1.22 - $2.48 $20,471 - $41,614	16,780 Added 4.63%	379,136 $474,000
Q2 2022 Aug 15, 2022	BUY	$1.63 - $3.46 $100,447 - $213,219	61,624 Added 20.49%	362,356 $855,000
Q1 2022 May 16, 2022	BUY	$2.66 - $6.49 $438,442 - $1.07 Million	164,828 Added 121.28%	300,732 $932,000
Q4 2021 Feb 14, 2022	BUY	$6.24 - $10.2 $848,040 - $1.39 Million	135,904 New	135,904 $863,000

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $35.9M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.